Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Stealth Bio Posts Disappointing Elamipretide Data From Mid-Stage Geographic Atrophy Study

  • Stealth BioTherapeutics Corp (NASDAQ:MITO) has announced topline data from its Phase 2 ReCLAIM-2 trial evaluating elamipretide in geographic atrophy (GA) secondary to dry age-related macular degeneration. 
  • Although the trial did not meet its primary endpoints, a key secondary endpoint showed that elamipretide categorically improved visual function for patients with GA. 
  • The study did not meet the primary endpoints of mean change in low luminance visual acuity (LLVA) and geographic atrophy (GA) progression.
  • Read Next: Stealth Bio's SBT-272 Shows Encouraging Action In Huntington's Disease Animal Model.
  • Additionally, elamipretide demonstrated proof of mechanism by reducing progressive ellipsoid zone loss, a key biomarker of retinal mitochondrial health. 
  • Elamipretide resulted in a two or more line gain in LLVA for greater than 15% of patients completing the 48-week trial (p=0.04). 
  • Although this improvement in visual function was not associated with reduced GA progression (primary endpoint), a significant reduction in ellipsoid zone loss (p=0.0034) was observed. 
  • Elamipretide was generally well tolerated in ReCLAIM-2. Injection site reactions were the most commonly observed adverse events and, in some cases, led to early termination.  
  • Price Action: MITO shares are down 23.40% at $0.31 during the premarket session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.